Analysis of the acetabular chondral flap (ALAD-3/4 damage) in FAI syndrome type CAM

Analysis of the acetabular chondral flap (ALAD-3/4 damage) in FAI syndrome type CAM - -

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023506

Enrollment

Registered

2020-11-04

Start date

2020-11-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M24.85 M94.25

Interventions

Group 1: The cartilage flap is resected intraoperatively in the presence of ALAD 3/4 damage. This will be evaluated histologically.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: FAI Syndrome, chondral damage ALAD 3/4

Exclusion criteria

Exclusion criteria: Chondral damage ALAD 1/2

Design outcomes

Primary

Measure	Time frame
Unstable chondral delamination flaps are routinely resected intraoperatively and examined. Histology: A portion of the resected tissue is fixed in paraformaldehyde for histological examination, embedded in kerosene and cut. For histological evaluation of cartilage quality, the following staining procedures are performed: (i) H&E as overview staining and for the evaluation of possible immune cell infiltrations (ii) Collagen (II) Immunofluorescence for the evaluation of cartilage quality or the proportion of hyaline articular cartilage (iii) Alcian blue for the evaluation of cartilage quality or the proportion of sulfated glycosaminoglycans.	—

Measure

Time frame

Unstable chondral delamination flaps are routinely resected intraoperatively and examined. Histology: A portion of the resected tissue is fixed in paraformaldehyde for histological examination, embedded in kerosene and cut. For histological evaluation of cartilage quality, the following staining procedures are performed: (i) H&E as overview staining and for the evaluation of possible immune cell infiltrations (ii) Collagen (II) Immunofluorescence for the evaluation of cartilage quality or the proportion of hyaline articular cartilage (iii) Alcian blue for the evaluation of cartilage quality or the proportion of sulfated glycosaminoglycans.

—

Secondary

Measure	Time frame
Flow cytometry: A part of the resectate is digested for cell isolation by collagenase degradation (Yonenaga et al. 2017). After degradation the cell counts / g resectate are quantified. To assess possible immune cell infiltration, the isolated cells are examined by flow cytometry. For this purpose a Basic Immune Phenotyping (CD3, CD4, CD8, CDM, CD16, CD19, CD45, CD56) is performed. Cell characterization: To assess the functionality of isolated chondrocytes, they are expanded in vitro and subsequently characterized, (i) proliferation capacity and viability, (ii) migration capacity (live cell imaging), (iii) matrix formation after chondrogenic in vitro stimulation and subsequent proteoglycan quantification, histological examination of the cartilage pellet and gene expression analyses of the classical chondrogenic markers (ACAN, MMP13, SOX9, COL10A1, COL2A1) before and after stimulation.	—

Measure

Time frame

Flow cytometry: A part of the resectate is digested for cell isolation by collagenase degradation (Yonenaga et al. 2017). After degradation the cell counts / g resectate are quantified. To assess possible immune cell infiltration, the isolated cells are examined by flow cytometry. For this purpose a Basic Immune Phenotyping (CD3, CD4, CD8, CDM, CD16, CD19, CD45, CD56) is performed. Cell characterization: To assess the functionality of isolated chondrocytes, they are expanded in vitro and subsequently characterized, (i) proliferation capacity and viability, (ii) migration capacity (live cell imaging), (iii) matrix formation after chondrogenic in vitro stimulation and subsequent proteoglycan quantification, histological examination of the cartilage pellet and gene expression analyses of the classical chondrogenic markers (ACAN, MMP13, SOX9, COL10A1, COL2A1) before and after stimulation.

—

Countries

Germany

Contacts

Public ContactAlexander Zimmerer

ARCUS Kliniken

zimmerer@sportklinik.de+49 7231 / 60556 - 312

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026